CN119173261A - 登革热病毒感染的治疗和/或预防 - Google Patents

登革热病毒感染的治疗和/或预防 Download PDF

Info

Publication number
CN119173261A
CN119173261A CN202380039672.0A CN202380039672A CN119173261A CN 119173261 A CN119173261 A CN 119173261A CN 202380039672 A CN202380039672 A CN 202380039672A CN 119173261 A CN119173261 A CN 119173261A
Authority
CN
China
Prior art keywords
fat
days
compound
day
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380039672.0A
Other languages
English (en)
Chinese (zh)
Inventor
O·阿克特
T·巴盖
C·巴尔曼
N·戈伊瓦茨
G·埃雷拉-塔拉塞纳
D·亨特詹斯
F·拉舍尔特
B·施罗恩
I·萨默斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CN119173261A publication Critical patent/CN119173261A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380039672.0A 2022-05-12 2023-05-01 登革热病毒感染的治疗和/或预防 Pending CN119173261A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341074P 2022-05-12 2022-05-12
US63/341074 2022-05-12
PCT/IB2023/054527 WO2023218285A1 (en) 2022-05-12 2023-05-01 Treatment or prevention of dengue viral infection

Publications (1)

Publication Number Publication Date
CN119173261A true CN119173261A (zh) 2024-12-20

Family

ID=86558745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380039672.0A Pending CN119173261A (zh) 2022-05-12 2023-05-01 登革热病毒感染的治疗和/或预防

Country Status (8)

Country Link
US (1) US20250281457A1 (enExample)
EP (1) EP4522163A1 (enExample)
JP (1) JP2025517683A (enExample)
CN (1) CN119173261A (enExample)
AU (1) AU2023269343A1 (enExample)
CA (1) CA3257185A1 (enExample)
TW (1) TW202400144A (enExample)
WO (1) WO2023218285A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN114980884A (zh) * 2019-11-15 2022-08-30 杨森制药公司 登革热疾病的治疗和预防

Also Published As

Publication number Publication date
JP2025517683A (ja) 2025-06-10
CA3257185A1 (en) 2023-11-16
US20250281457A1 (en) 2025-09-11
AU2023269343A1 (en) 2025-01-02
TW202400144A (zh) 2024-01-01
EP4522163A1 (en) 2025-03-19
WO2023218285A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
US20210315900A1 (en) Solid dosage forms of palbociclib
KR101512404B1 (ko) 디하이드로피리딘 칼슘 채널 길항제를 포함하는 향상된 의약 조성물 및 이의 준비 방법
TW201238612A (en) Therapeutic compositions
NO344546B1 (no) Legemiddelformuleringer med forbedrede farmakokinetiske egenskaper inneholdende vardenafil
JP7444967B2 (ja) ４－アミノ－３－置換ブタン酸誘導体の安定化製剤
EP4240331B1 (en) Solid formulation
US20170014340A1 (en) Orally Disintegrating Tablet of Nabilone Comprising Mannitol-Based Granules
KR102286386B1 (ko) 아타자나비르 및 코비시스타트의 ｈｉｖ 치료 제제
US11696895B2 (en) Fine particle coating (drug-containing hollow particle and method for manufacturing same)
KR20040007665A (ko) 파라세타몰을 포함하는 연하 정제
WO2005051350A2 (en) Water dispersible tablet
JP6639368B2 (ja) 糖尿病治療用固形製剤
US20250281457A1 (en) Treatment or prevention of dengue viral infection
WO2020089760A1 (en) Fixed dose pharmaceutical composition comprising combination of remogliflozin or salt or ester thereof and vildagliptin or salt thereof
HK40120143A (zh) 登革热病毒感染的治疗和/或预防
RU2674978C2 (ru) Фармацевтическая композиция N-[5-[2-(3,5-диметоксифенил)этил]-2H-пиразол-3-ил]-4-[(3R,5S)-3,5-диметилпиперазин-1-ил]бензамида
CN118284415A (zh) 一种达罗他胺药物组合物及其制备方法和用途
JP4866170B2 (ja) 睡眠薬の放出制御医薬組成物及びその製造方法
TWI923631B (zh) 固體配製物
JPWO2003075919A1 (ja) 塩酸ピルジカイニド含有錠剤（乾式）
US20130035344A1 (en) Pharmaceutical composition for oral administration
HK40099185A (zh) 固体制剂
US11096945B2 (en) Pharmaceutical compositions of linagliptin and process for preparation thereof
EP3335703A1 (en) Pharmaceutical composition comprising omarigliptin
CA2473602A1 (en) Oral pediatric trimethobenzamide formulations and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40120143

Country of ref document: HK